



**Matthias Guckenberger**

**Kontakt**

Matthias Guckenberger

## ■ Publikationen (20)

Gassner M, Barranco Garcia J, Tanadini-Lang S, Bertoldo F, Fröhlich F, Guckenberger M, Haueis S, Pelzer C, Reyes M, Schmithausen P, Simic D, Stäger R, Verardi F, Andratschke N, Adelmann A, Braun R. Saliency-Enhanced Content-Based Image Retrieval for Diagnosis Support in Dermatology Consultation: Reader Study. *JMIR Dermatol* 2023; 6:e42129.

König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. *ESMO Open* 2023; 8:101595.

Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). *Br J Clin Pharmacol* 2022; 88:5336–5347.

Achard V, Putora P, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Meersschout S, Guckenberger M, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefooghe N, Otte F, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Zilli T. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. *Radiother Oncol* 2022; 172:1–9.

Beck M, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti D, Reuter C, Gomez S, Khanfir K, Aebersold D, Ghadjar P, Schär C, Hayoz S, Papachristofilou A, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen D, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller A, Putora P, Pra A. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. *Int J Radiat Oncol Biol Phys* 2022; 113:80–91.

Kroeze S, Schymalla M, Abbasi-Senger N, Buergy D, Geier M, Szuecs M, Lohaus F, Henke G, Combs S, Stera S, Adebarh S, Sundahl N, Fritz C, Schaulé J, Blanck O, Kahl K, Kaul D, Siva S, Gerum S, Claes A, Guckenberger M. Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. *Cancers (Basel)* 2021; 13

Süveg K, McDonald F, Dziadziszko R, Belderbos J, Ricardi U, Manapov F, Lievens Y, Geets X, Dieckmann K, Guckenberger M, Andratschke N, Nestle U, Peeters S, Le Pechoux C, Faivre-Finn C, Putora P, De Ruysscher D, Widder J, Van Houtte P, Troost E, Slotman B, Ramella S, Pöttgen C, Glatzer M. Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. *Clin Lung Cancer* 2021; 22:579–586.

Ghadjar P, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D, Kaouthar K, Gomez S, Wust P, Thalmann G, Aebersold D, Sumila M, Schär C, Hayoz S, Bernhard J, Zwahlen D, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A, Plasswilm L, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. *Eur Urol* 2021; 80:306–315.

Tamò R, Turk T, Böni J, Kouyos R, Schmutz S, Huber M, Shah C, Bischoff-Ferrari H, Distler O, Battegay E, Giovanoli P, Guckenberger M, Kohler M, Müller R, Petry H, Ruschitzka F, McGeer A, Sax H, Weber R, Trkola A, Kuster S. Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. *Infect Control Hosp Epidemiol* 2021; 43:312–318.

Glatzer M, Kocher G, Kraxner P, Krueger T, Martucci F, Oehler C, Ozsahin M, Papachristofilou A, Wagnetz D, Zaugg K, Zwahlen D, Opitz I, Kestenholz P, Karenovics W, Leskow P, Caparrotti F, Elicin O, Furrer M, Gambazzi F, Dutly A, Gelpke H, Guckenberger M, Heuberger J, Inderbitzi R, Cafarotti S, Putora P. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. *Transl Lung Cancer Res* 2021; 10:1960-1968.

Kroeze S, Eckert F, Lohaus F, Sackerer I, Skazikis G, Geier M, Szuecs M, Glatzer M, Schymalla M, Adebarh S, Verhoeff J, Siva S, Roeder F, Kahl K, Blanck O, Kaul D, Fritz C, Schaule J, Guckenberger M. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaST' database. *Radiat Oncol* 2021; 16:4.

Schaule J, Lohaus F, Abbasi-Senger N, Henke G, Szuecs M, Geier M, Sundahl N, Buergy D, Dummer R, Eckert F, Adebarh S, Schymalla M, Kroeze S, Blanck O, Stera S, Kahl K, Roeder F, Combs S, Kaul D, Claes A, Guckenberger M. Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. *Radiat Oncol* 2020; 15:280.

Glatzer M, Dziadziszko R, Belderbos J, Ricardi U, Manapov F, Lievens Y, Geets X, Dieckmann K, Guckenberger M, Andratschke N, Süveg K, Le Pechoux C, McDonald F, Faivre-Finn C, De Ruysscher D, Widder J, Van Houtte P, Troost E, Slotman B, Ramella S, Pöttgen C, Peeters S, Nestle U, Putora P. Role of radiotherapy in the management of brain metastases of NSCLC - Decision criteria in clinical routine. *Radiother Oncol* 2020; 154:269-273.

Achard V, Matzinger O, Peguret N, Pesce G, Putora P, Reuter C, Richetti A, Vees H, Vrieling C, Zaugg K, Zimmermann F, Zwahlen D, Tsoutsou P, Kaouthar K, Huck C, Herrmann E, Aebersold D, Allal A, Andratschke N, Baumert B, Beer K, Betz M, Breuneval T, Bodis S, De Bari B, Förster R, Franzetti-Pellanda A, Guckenberger M, Zilli T. A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. *Radiother Oncol* 2020; 150:1-3.

Schaule J, Lohaus F, Abbasi-Senger N, Henke G, Szuecs M, Geier M, Sundahl N, Buergy D, Dummer R, Eckert F, Adebarh S, Schymalla M, Kroeze S, Blanck O, Stera S, Kahl K, Roeder F, Combs S, Kaul D, Claes A, Guckenberger M. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. *Radiat Oncol* 2020; 15:135.

Elicin O, Giger R, Spielmann T, Prestwich R, Riesterer O, Kaydihan N, Shelan M, Guckenberger M, Ozsahin M, Anschuetz L, Adam L, Henke G, Studer G, Zimmermann F, Caparrotti F, Aebersold D, Oehler C, Ermiş E, Şen M. Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study. *Front Oncol* 2019; 9:932.

Müller J, von Schulthess G, Kaufmann P, Kranzbuehler H, John H, Zilli T, Müller A, Omlin A, Schmid D, Sulser T, Kroeze S, Guckenberger M, Eberli D, Kedzia S, Garcia Schüler H, Muehlematter U, Ferraro D, Burger I. Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. *Eur J Nucl Med Mol Imaging* 2018

Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). *J Thorac Oncol* 2018

Ghadjar P, Kranzbühler H, Najafi Y, Ost P, Azinwi N, Reuter C, Bodis S, Kaouthar K, Budach V, Aebersold D, Thalmann G, Sumila M, Biaggi-Rudolf C, Stalder L, Hayoz S, Genitsch V, Zwahlen D, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller A, Putora P, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. *BJU Int* 2017; 120:E45-E51.

Sassowsky M, Takacs I, Reuter C, Sumila M, Manser P, Ost P, Böhmer D, Pilop C, Aebersold D, Plasswilm L, Azinwi N, Zwahlen D, Gut P, Hölscher T, Hildebrandt G, Müller A, Najafi Y, Kohler G, Kranzbühler H, Guckenberger M, Ghadjar P. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10. *Int J Radiat Oncol Biol Phys* 2013; 87:534-41.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)